Drug discovery memory
that compounds over time.

Drug discovery campaigns span months to years — with AI-assisted hypothesis generation, compound screening, and SAR analysis spread across hundreds of sessions. Without persistent memory, every session re-ingests the full campaign context: known failures, active hypotheses, structural constraints, literature anchors. CLEOS captures the complete campaign context at the first session and injects only the relevant portions on subsequent sessions — eliminating cold-start waste while ensuring that failed compounds are never re-screened because the AI forgot they failed. The system compounds intelligence with every session: what failed in Month 1 informs Month 6 without requiring any researcher to re-brief the AI on known history.

Every AI-generated statement in a regulatory submission — efficacy summary, safety analysis, comparative effectiveness assessment — must be traceable to its source data and reasoning chain under FDA’s 2025 draft guidance. CLEOS captures the complete reasoning chain for every AI-generated clinical or scientific statement: what source data was accessed, what analytical framework was applied, what alternative conclusions were considered, and what human review was performed. This provenance documentation is generated automatically — not reconstructed manually before submission. For organizations submitting multiple INDs and NDAs per year, the time savings alone (typically 200-400 hours per submission for AI audit documentation) pay for CLEOS infrastructure many times over.

Phase II and III clinical trials operate across dozens of sites — with AI agents supporting enrollment screening, adverse event analysis, protocol deviation monitoring, and interim efficacy analysis. CLEOS enables these agents to share relevant cross-site context (enrollment trends, AE signals, protocol clarifications) while maintaining strict site-level data isolation (no site’s patient data is accessible to agents serving other sites). For Safety Monitoring Board AI tools, CLEOS provides the full audit trail of every AI-assisted unblinded analysis — satisfying the oversight documentation requirements that trial integrity protocols mandate. For CROs managing multiple sponsor programs, CLEOS enforces sponsor-level data walls automatically.